Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

QRxPharma successfully completes phase III pilot study of MoxDuo IR

April 22, 2009

Taisho presents novel heterocyclic compounds for the treatment of pain

April 22, 2009

Alkylsulfone derivatives claimed by Daiichi Sankyo for the treatment of Alzheimer's disease

April 22, 2009

Psylin Neurosciences begins development of PSN-004 for depression

April 21, 2009

Phytopharm initiates safety and tolerability study of PYM-50028 in PD

April 21, 2009

Forest and Cypress launch Savella for fibromyalgia

April 21, 2009

Impax provides clinical update on IPX-066 and IPX-056

April 21, 2009

Cannabinoid CB2 modulators claimed by Kalypsys as analgesics

April 21, 2009

PAION initiates phase Ib study of CNS-7056 in volunteers undergoing colonoscopy

April 20, 2009

Dainippon discontinues development of AC-3933 for dementia

April 20, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...